Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Louis Jacques On Coverage, Evidence And IDEs

This article was originally published in The Gray Sheet

Executive Summary

In the first part of a two-part Q&A, just-departed CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.


Related Content

Local Coverage With Evidence Development Is Legit, CMS Says; But It May Be Rare
More Cohesive Coverage-With-Evidence Authority Needed, Lawmakers Told
Ex-CMS Louis Jacques On Partnering With FDA And Keeping It Local
CMS Coverage Group Changes Management, But Not Priorities
CDRH Preps New Program To Streamline Approval-To-Reimbursement Path
Final Coverage-With-Evidence-Development Guidance Delayed By CMS Staff Cuts
FDA-CMS Parallel Review Saves Time, Clinical Trial Costs, Participant Says
CMS Ambiguous On Role Of Local Contractors In Coverage With Evidence Development
CDRH Entrepreneurs Take Two: Streamlining Data Collection And The Path To Reimbursement





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts